- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05332561
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)
Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer - a Multicenter, Open-label, Umbrella Phase-II Study - COGNITION-GUIDE
In early breast cancer (eBC), pathological complete response (pCR) after neoadjuvant therapy acts as surrogate marker for metastasis and overall survival. Therapy intensification by adding an adjuvant therapy line (post-neoadjuvant treatment) substantially lowers the risk of relapse in high-risk breast cancer patients with residual disease after neoadjuvant treatment (non-pCR). While this approach was exemplified in two phase III trials without biomarker-stratification (CREATE-X, KATHERINE), even higher efficiency might be achieved by individualized genomic-guided post-neoadjuvant therapies.
Within the seven-arm umbrella phase-II clinical trial COGNITION-GUIDE, we aim to deliver molecularly-tailored cancer care by implementing an additional response- and genomics-guided post-neoadjuvant therapy after finishing the guideline-compliant post-neoadjuvant treatment in high-risk breast cancer patients with residual cancer burden after neoadjuvant therapy to reduce the substantial risk of local and distant relapse.
The trial evaluates not a single drug but rather a general strategy of precision oncology in the curative setting and provides the basis for future confirmatory biomarker-driven trials.
Allocation to the therapy-arms is conducted by in depth molecular characterization of tumors within the COGNITION registry program.
The study aims to show an overall benefit of the precision medicine approach in high-risk eBC patients and to allow for secondary exploratory evaluation of each study-arm.
The primary endpoint of the study is invasive Disease-Free Survival (IDFS) after 4 years measured from surgery to local or distant relapse or death. The sample size of the entire trial is 240 eligible patients.
Study Overview
Status
Conditions
Detailed Description
In early breast cancer (eBC), pathological complete response (pCR) after neoadjuvant therapy acts as surrogate marker for metastasis and overall survival.
Therapy intensification by adding an adjuvant therapy line (post-neoadjuvant treatment) substantially lowers the risk of relapse in high-risk breast cancer patients with residual disease after neoadjuvant treatment (non-pCR).
While this approach was exemplified in two phase III trials without biomarker-stratification (CREATE-X, KATHERINE), even higher efficiency might be achieved by individualized genomic-guided post-neoadjuvant therapies.
To date, prospective whole genomic and transcriptomic sequencing in the framework of precision oncology concepts is predominantly conducted in advanced-stage cancer, limiting the overall benefit mainly to prolongation of progression-free survival rather than cure.
In contrast, the implementation of precision oncology in an early disease stage may empower targeted intervention based on high throughput sequencing at a time point with low tumor burden and limited clonal complexity, harbouring the prospect to substantially improve cure rates by prohibition of incurable metastasis.
Whole-genome (WGS), whole exome (WES), gene panel and transcriptome sequencing in the molecular diagnostic registry platform COGNITION (neoadjuvant-treated eBC patients) revealed relevant diagnostic information on molecular-druggable alterations in a substantial proportion of patients in different molecular pathways (e.g. phosphatidylinositol 3-kinase (PI3K)/ serine/threonine kinase (AKT), Mitogen-activated protein kinase (MAPK), apoptosis, DNA-repair, immune escape etc.).
Within the seven-arm umbrella phase-II clinical trial COGNITION-GUIDE, we aim to deliver molecularly-tailored cancer care by implementing an additional response- and genomics-guided post-neoadjuvant therapy after finishing the guideline-compliant post-neoadjuvant treatment in high-risk breast cancer patients with residual cancer burden after neoadjuvant therapy to reduce the substantial risk of local and distant relapse.
The trial evaluates not a single drug but rather a general strategy of precision oncology in the curative setting and provides the basis for future confirmatory biomarker-driven trials.
Eligible patients are identified considering pCR-status and clinical stage estrogen receptor status grade (CPS-EG)-score following surgery after neoadjuvant therapy.
Allocation to the therapy-arms is conducted by in depth molecular characterization of tumors within the COGNITION registry program.
Recruitment of adequate patient numbers in well-defined molecular subgroups is achieved in a multicenter approach.
The study aims to show an overall benefit of the precision medicine approach in high-risk eBC patients and to allow for secondary exploratory evaluation of each study-arm.
The primary endpoint of the study is invasive Disease-Free Survival (IDFS) after 4 years measured from surgery to local or distant relapse or death.
The sample size of the entire trial is 240 eligible patients.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Andreas Schneeweiss, Prof. Dr.
- Phone Number: 36051 +49(0)622156
- Email: andreas.schneeweiss@med.uni-heidelberg.de
Study Contact Backup
- Name: Richard Schlenk, Prof. Dr.
- Email: richard.schlenk@nct-heidelberg.de
Study Locations
-
-
-
Berlin, Germany
- Not yet recruiting
- Charité - Universitätsmedizin Berlin
-
Contact:
- Jens Blohmer, Prof. Dr.
- Phone Number: 172 +49 (0)30 450 564
- Email: jens.blohmer@charite.de
-
-
Baden-Wuerttemberg
-
Heidelberg, Baden-Wuerttemberg, Germany, 69120
- Recruiting
- National Center for Tumor Diseases
-
Contact:
- Andreas Schneeweiss, Prof. Dr.
- Email: andreas.schneeweiss@med.uni-heidelberg.de
-
-
Bayern
-
Erlangen, Bayern, Germany, 91054
- Not yet recruiting
- Universitätsklinikum Erlangen
-
Contact:
- Peter Fasching, Prof. Dr.
- Phone Number: 33553 +49 (0)9131 85
- Email: peter.fasching@uk-erlangen.de
-
Ulm, Bayern, Germany, 89075
- Not yet recruiting
- Universitatsklinikum Ulm
-
Contact:
- Wolfgang Janni, Prof. Dr.
- Phone Number: 58501 +49 (0)731 500
- Email: Janni_Studien.UKF@uniklinik-ulm.de
-
-
Sachsen
-
Dresden, Sachsen, Germany, 01397
- Not yet recruiting
- Universitätsklinikum Carl-Gustav-Carus
-
Contact:
- Pauline Wimberger, Prof. Dr.
- Phone Number: 6728 +49 (0)351 458
- Email: Pauline.Wimberger@uniklinikum-dresden.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of written informed consent
- Female and male patients with non-metastatic early (stage I-III) breast cancer aged ≥ 18 years
- Conducted neoadjuvant chemotherapy and surgery as well as conducted standard post-neoadjuvant treatment +/- radiotherapy (standard according to German guidelines except Abemaciclib and Olaparib)
For patients with initially triple negative (TNBC) or HER2-positive breast cancer:
• Non-pCR defined as other than ypT0/is ypN0
For patients with initially hormone receptor positive and HER2-negative breast cancer: Non-pCR and CPS-EG score
- ≥ 3 and ypN0, or
- ≥ 2 and ypN+
- ECOG Performance Status ≤ 1
- Acute effects of any prior therapy resolved to baseline severity or National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 (NCI CTCAE v5.0) Grade ≤ 1 except for adverse effects not constituting a safety risk by investigator judgement
Postmenopausal or evidence of non-childbearing status. For women of childbearing potential negative urine pregnancy test at post-operative screening and baseline as well as highly effective forms of contraception have to be in place thereafter
- Evidence of childbearing potential is defined as fertile, following menarche and until becoming post-menopausal unless permanently sterile
Postmenopausal or evidence of non-childbearing status is defined as:
- Amenorrhea for 1 year or more without an alternative medical cause following cessation of exogenous hormonal treatments plus follicle stimulating hormone (FSH) levels in the postmenopausal range in women not using hormonal contraception or hormonal replacement therapy
- Chemotherapy-induced menopause
- Surgical sterilisation (bilateral oophorectomy, bilateral salpingectomy, total hysterectomy or tubal ligation at least 6 weeks before IMP treatment)
- Female patients with age ≥ 60 years
- A man is considered fertile after puberty unless permanently sterile by bilateral orchidectomy
- Female patients of childbearing potential and male patients with partners of childbearing potential who are sexually active must agree to the use of two forms of contraception in combination (male condom and one highly effective method). These should be started immediately after signing the informed consent form and continued throughout the period of study treatment plus a substance-depending time period (see respective sub-protocol) for female patients and a substance-depending time period for male patients. Details on contraception and pregnancy testing for male and female patients (and if indicated their partners) under IMP treatment are described within the respective sub-protocol
- Ability of patient to understand and comply with the protocol for the duration of the study, including treatment and scheduled visits and examinations
- Adequate bone marrow, renal, and hepatic function defined by laboratory tests*
The biomarker-guided eligibility for the respective study arm is evaluated and determined exclusively by the NCT molecular tumor board on the basis of results of the COGNITION molecular diagnostic registry platform. Biomarkers that allow inclusion in the respective arm are:
- Arm 1 (Atezolizumab, Immune Evasion ): PD-L1 positivity measure by IHC (≥1% on immune cells within the tumor), MSI-high status (validated by PCR), TMB-H (≥10mut/MB), CD274 amplification
- Arm 2 (Inavolisib, PI3K): Known/reported oncogenic mutation in PIK3Ca
- Arm 3 (Ipatasertib, AKT): Aberrations predicting increased PI3K-AKT pathway activity except PI3K-mutations, HR positive histology
- Arm 4 (Olaparib, PARP, DNA-Repair): Inactivating somatic or germline BRCA1/2 mutation including homozygous deletions, Inactivating germline PALB2 mutations
- Arm 5 (Sacituzumab Govitecan, TROP-2): Trop-2-overexpression (with IHC and except known/reported homozygous polymorphism in UGT1A1*28)
- Arm 6 (Trastuzumab / Pertuzumab, ERBBB): HER2 exon-20 insertion, Activating HER2-mutation
Exclusion Criteria:
- Other malignancy within the last 5 years except: adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, ductal carcinoma in situ (DCIS), Stage 1 grade 1 endometrial carcinoma, or other solid tumours including lymphomas (without bone marrow involvement) curatively treated with no evidence of disease for ≥ 5 year
- Concurrent severe, uncontrolled systemic disease that would place patient at undue risk or interfere with planned treatment
- Concurrent participation or previous treatment within 30 days in another interventional clinical trial
- Persistent toxicity (≥ Grade 2 according to NCI CTCAE v5.0 caused by previous cancer therapy, excluding alopecia
- Clinical signs of active infection (> Grade 2 according NCI CTCAE v5.0)
- History of or newly diagnosed human immunodeficiency virus (HIV) infection and immunocompromised patients
- Active Hepatitis A virus infection
- Active hepatitis B virus (HBV) infection, defined as having a positive hepatitis B surface antigen (HBsAg) test. Patients with a past or resolved HBV infection, defined as having a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test at screening, are eligible for the study if active HBV infection is ruled out on the basis of HBV DNA viral load per local guidelines
- Active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test at screening confirmed by a polymerase chain reaction (PCR) positive for HCV RNA
- Dementia or significant impairment of cognitive state
- Epilepsy requiring pharmacologic treatment
- Pregnancy and breast feeding
- Inability to take oral medication and gastrointestinal disorders likely to interfere with absorption of study medication
- Major surgery (any invasive operative procedure in which a more extensive resection is performed, e.g. a body cavity is entered, organs are removed, or normal anatomy is altered) within four weeks before screening and baseline excluding breast-tumor resection after neoadjuvant chemotherapy. Patients must have recovered from any effects of any major surgery
- Systemic chemotherapy or radiotherapy within four weeks or a longer period depending on the characteristics of the agents used
- Heart failure classified as New York Heart Association (NYHA) II/III/IV
- Severe obstructive or restrictive ventilation disorder
- Patients with clinically active tuberculosis
- Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug
- Is taking or requiring the continued use of any of the prohibited concomitant medications listed in the respective subprotocols at baseline
- Patients considered a poor medical risk due to a serious, uncontrolled medical disorder or non-malignant systemic disease. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, unstable spinal cord compression or, superior vena cava syndrome.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 Atezolizumab (Immune Evasion)
Atezolizumab Dosage: 1200 mg, intravenous, on d1, q21d
|
Arm 1
Other Names:
|
Experimental: Arm 2 Inavolisib (PI3K)
Inavolisib Dosage: 9 mg, oral, on d1-d28, q28d
|
Arm 2
|
Experimental: Arm 3 Ipatasertib (AKT)
Ipatasertib Dosage: 400 mg, oral, on d1-d21, q28d
|
Arm 3
|
Experimental: Arm 4 Olaparib (PARP, DNA-Repair)
Olaparib Dosage: 300 mg, oral, bid d1-d28, q28d
|
Arm 4
Other Names:
|
Experimental: Arm 5 Sacituzumab Govitecan (TROP-2)
Sacituzumab Govitecan Dosage: 10 mg/kg BW, intravenous, on d1 and d8, q21d
|
Arm 5
Other Names:
|
Experimental: Arm 6 Trastuzumab/Pertuzumab (ERBBB)
Trastuzumab/Pertuzumab Administration: subcutaneous; Initial dose: Trastuzumab 600 mg, Pertuzumab 1200 mg, 30 000 units hyaluronidase; Maintainance dose: Trastuzumab 600 mg, Pertuzumab 600 mg, 20 000 units hyaluronidase; Frequency: on d1, q21d
|
Arm 6
Other Names:
|
No Intervention: Arm 7 Observation
Observation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Invasive Disease-free Survival (IDFS) as defined by Hudis et al in the entire study population four years after surgery
Time Frame: Four years after surgery
|
Primary objective is to improve clinical outcome in early high-risk breast cancer by biomarker-guided post-neoadjuvant therapy (systemic treatment in the adjuvant setting following neoadjuvant therapy, surgery and post-neoadjuvant standard therapy)
|
Four years after surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Invasive Disease-free Survival (IDFS) as defined by Hudis et al
Time Frame: Four years after surgery
|
in each study arm separately
|
Four years after surgery
|
Distant Disease-free Survival (DDFS) as defined by Hudis et al
Time Frame: Four years after surgery
|
in each study arm separately and overall
|
Four years after surgery
|
Overall Survival
Time Frame: When the last patient has completed four years after surgery
|
in each study arm separately and overall
|
When the last patient has completed four years after surgery
|
Incidence of Treatment-Emergent Adverse Events (safety and tolerability)
Time Frame: Through treatment period of the study, an average of 1 year
|
in each study arm separately and overall
|
Through treatment period of the study, an average of 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Andreas Schneeweiss, Prof. Dr., National Center for Tumor Diseases (NCT)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors
- Immune Checkpoint Inhibitors
- Phosphoinositide-3 Kinase Inhibitors
- Immunoconjugates
- Trastuzumab
- Olaparib
- Atezolizumab
- Pertuzumab
- Ipatasertib
- Sacituzumab govitecan
- Inavolisib
Other Study ID Numbers
- DKFZ-2019-008
- 2020-002606-22 (EudraCT Number)
- 01EK2202A (Other Grant/Funding Number: Bundesministerium für Bildung und Forschung - BMBF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Early-stage Breast Cancer
-
Dana-Farber Cancer InstituteCompletedEarly Stage Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage IIUnited States
-
Jonsson Comprehensive Cancer CenterDaiichi Sankyo Co., Ltd.; Translational Research in Oncology-U.SRecruitingInvasive Breast Cancer | Stage II Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Hormone Receptor Positive Breast Carcinoma | Early-stage Breast Cancer | Stage III Breast CancerUnited States
-
Tanvex BioPharma USA, Inc.CompletedBreast Cancer | Breast Neoplasms | HER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Early-stage Breast CancerBelarus, Chile, Georgia, Hungary, India, Mexico, Peru, Philippines, Russian Federation, Ukraine
-
Stanford UniversityTerminatedBreast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Metastatic Breast CancerUnited States
-
Stanford UniversityNational Institutes of Health (NIH); University of California; Breast Cancer... and other collaboratorsActive, not recruitingBreast Cancer | Breast Cancer Non-invasive Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3)United States
-
University of Wisconsin, MadisonRecruitingEarly-stage Breast CancerUnited States
-
Shandong Cancer Hospital and InstituteRecruitingEarly-stage Breast Cancer | Breast Conserving SurgeryChina
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingStage 0 Breast Cancer | Cancer Survivor | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Early-Stage Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast CancerUnited States
-
MedStar Franklin Square Medical CenterMedstar Health Research InstituteActive, not recruitingEarly Stage Breast CancerUnited States
-
Fudan UniversityHuazhong University of Science and Technology; LinkDoc Technology (Beijing)...RecruitingEarly-stage Breast CancerChina
Clinical Trials on Atezolizumab 1200 mg in 20 ML Injection
-
University of Michigan Rogel Cancer CenterWithdrawnProstate CancerUnited States
-
Gruppo Oncologico Italiano di Ricerca ClinicaRecruitingMesotheliomas PleuralItaly
-
Adlai Nortye Biopharma Co., Ltd.RecruitingLocally Advanced Solid TumorUnited States
-
Fondazione Melanoma OnlusClinical Research Technology S.r.l.Active, not recruiting
-
Instituto Oncológico Dr RosellRoche Pharma AG; Fundacion Clinic per a la Recerca BiomédicaActive, not recruitingExtensive-stage Small Cell Lung CancerSpain
-
Advanz PharmaAstellas Pharma US, Inc.CompletedAtrial FlutterUnited States, Canada, Denmark, Sweden
-
Advanz PharmaAstellas Pharma US, Inc.CompletedAtrial FibrillationUnited States, Canada, Sweden, Denmark
-
Palleos Healthcare GmbHRoche Pharma AG; University Hospital, Essen; University Hospital Erlangen; Phaon...Active, not recruitingTriple-negative Breast CancerGermany
-
Basilea PharmaceuticaCompletedUrothelial CarcinomaUnited Kingdom, Korea, Republic of, Italy, Canada, France, Spain, Germany, United States, Hungary, Australia, Poland, Switzerland, Czechia, Austria
-
Affimed GmbHRecruitingAdvanced Solid TumorUnited States, Spain, United Kingdom, Korea, Republic of, Poland